A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome.

ABSTRACT:

Objective

To compare the efficacy and safety of a new porcine-derived pulmonary surfactant developed by Instituto Butantan with those of animal-derived surfactants commercially available in Brazil, regarding neonatal mortality and the major complications of prematurity in preterm newborns with birth weight up to 1500g and diagnosed with respiratory distress syndrome.

Methods

Neonates diagnosed with respiratory distress syndrome were randomized to receive either Butantan surfactant (Butantan group) or one of the following surfactants: Survanta® or Curosurf®. Newborns receiving Survanta® or Curosurf® comprised the control group. The main outcome measures were mortality rates at 72 hours and at 28 days of life; the typical complications of prematurity as evaluated on the 28th d

SUBMITTER: Rebello CM 

PROVIDER: S-EPMC4879903 | biostudies-literature | 2014 Oct-Dec

REPOSITORIES: biostudies-literature